SEARCH:   Advanced

Blood, 15 September 2005, Vol. 106, No. 6, pp. 1911-1923. Prepublished online as a Blood First Edition Paper on March 31, 2005; DOI 10.1182/blood-2004-12-4621. This Article Full Text (PDF) All Versions of this Article: 2004-12-4621v1 106/6/1911    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hachem, A. Articles by Gartenhaus, R. B Search for Related Content PubMed PubMed Citation Articles by Hachem, A. Articles by Gartenhaus, R. B Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 14, 2004 Accepted March 27, 2005 Oncogenes as molecular targets in lymphoma Ali Hachem and Ronald B Gartenhaus* University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA * Corresponding author; email: rgartenhaus{at}som.umaryland.edu. The activation of oncogenes is essential to the development of lymphoid malignancies. Frequently, these oncogenes are involved in relaying extra-cellular messages to the nucleus by means of signaling pathways, causing changes in the cell transcriptional patterns. The altered function of those molecules associated with lymphomagenesis presents unique opportunities to specifically disrupt those signaling pathways critical to maintaining the malignant phenotype. Distinct oncogenic signaling cascades have been specifically associated with the different subtypes of non-Hodgkins lymphoma. Many of the effectors involved in these pathways may be essential for signaling function, thus offering an expansive array of candidate targets. Targeted therapeutic approaches are more likely to be specific and associated with fewer deleterious side effects. They are also expected to be highly active. Diverse and novel strategies have been utilized to target the products of these oncogenes in non-Hodgkins lymphoma; several have already reached the clinic with promising preliminary results. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Feitsma, R. V. Kuiper, J. Korving, I. J. Nijman, and E. Cuppen Zebrafish with Mutations in Mismatch Repair Genes Develop Neurofibromas and Other Tumors Cancer Res., July 1, 2008; 68(13): 5059 - 5066. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020